SCHEMBL195680

SCHEMBL195680

[CH2]CCCCS(N)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5200383 0.97 CA2 (0.39)
SCHEMBL27607021 0.97 CA2 (0.39)
SCHEMBL27607145 0.97 CA2 (0.39)
SCHEMBL4392695 0.97 CA2 (0.39)
SCHEMBL27625464 0.97 CA2 (0.39)
SCHEMBL483134 0.91
SCHEMBL10457263 0.84 CA2 (0.43)
SCHEMBL10798852 0.81 CA2 (0.48)
SCHEMBL11147913 0.81 CA2 (0.48)
SCHEMBL30041571 0.81 CA2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107602620-B Novel iridium-based complexes for ECL 霍夫曼-拉罗奇有限公司 2020-08-28 CN claimed
CN-107602620-A Novel iridium base complex for ECL 霍夫曼-拉罗奇有限公司 2018-01-19 CN claimed
EP-2880043-B1 NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS ROCHE DIAGNOSTICS GMBH (DE) 2016-09-21 EP claimed
EP-2880043-A1 NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS Roche Diagnostics GmbH (DE) 2015-06-10 EP claimed
US-20150148536-A1 NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) 2015-05-28 US claimed
WO-2014019710-A1 NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS ROCHE DIAGNOSTICS GMBH (DE) 2014-02-06 WO claimed
EP-4373493-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY Nurix Therapeutics, Inc. (US) 2024-05-29 EP disclosed
EP-4370123-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY Nurix Therapeutics, Inc. (US) 2024-05-22 EP disclosed
WO-2024086296-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K MEKANISTIC THERAPEUTICS LLC (US) 2024-04-25 WO disclosed
US-20240124475-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. 2024-04-18 US disclosed
US-20240092766-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2024-03-21 US disclosed
EP-4334303-A1 COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE Nurix Therapeutics, Inc. (US) 2024-03-13 EP disclosed
EP-4334302-A1 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE Nurix Therapeutics, Inc. (US) 2024-03-13 EP disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 EP disclosed
WO-2005092907-A2 MONOSACCHARIDE DERIVATIVES AS ANTI-CANCER AND ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2005-10-06 WO disclosed
EP-0215435-B1 2-OXA-ISOCEPHEM COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-03-03 EP disclosed
US-4831026-A ANTIBIOTICS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-05-16 US disclosed
EP-0215435-A1 2-Oxa-isocephem compounds, compositions containing same and processes for preparing same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-03-25 EP disclosed
EP-0003784-A1 Distyryl compounds, their manufacture and use as bleaching agents and laser dyestuff BAYER AG (DE) 1979-09-05 EP disclosed
US-4156732-A Certain pharmaceutical sulfamoylbenzoyl benzofurans, benzothiophenes, and indoles HOECHST AKTIENGESELLSCHAFT (DE) 1979-05-29 US disclosed